Who
Michael H. Davidson
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, NewAmsterdam Pharma Company; Director, BioAge Labs; Director, Tenax Therapeutics; Director, Silence Therapeutics; Director, Lisata Therapeutics; Executive VP & CMO, Omthera Pharmaceuticals.
In numbers
- Trades disclosed
- 76
- Buys
- 5
- Sells
- 6
- Bought
- $721K
- Sold
- $50.7M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 16 Apr 2013
- Last trade
- 14 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 15 Sep 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $227K10,000 at $22.65 | filing |
| 14 Sep 2026filed 15 Sep 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Bought | $227K10,000 at $22.65 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —443,707 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $14.8M443,707 at $33.25 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —443,707 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —443,707 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —443,707 | filing |
| 2 Mar 2026filed 2 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $14.8M443,707 at $33.25 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $617K17,924 at $34.44 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —183,332 at $0.00 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —183,332 at $0.00 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —183,332 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —183,332 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $5.6M165,408 at $33.63 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $617K17,924 at $34.44 | filing |
| 26 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $5.6M165,408 at $33.63 | filing |
| 25 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —58,253 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —58,253 at $0.00 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)NAMS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Michael H. Davidson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.